1
|
Zhao L, Xie WJ, Du YX, Xia YX, Liu KL, Ku CF, Ou Z, Wang MZ, Zhang HJ. Isolation and Anticancer Progression Evaluation of the Chemical Constituents from Bridelia balansae Tutcher. Molecules 2023; 28:6165. [PMID: 37630417 PMCID: PMC10457964 DOI: 10.3390/molecules28166165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 08/16/2023] [Accepted: 08/17/2023] [Indexed: 08/27/2023] Open
Abstract
The dichloromethane extract of the roots of Bridelia balansae Tutcher (Phyllanthaceae) was found to show potential anticancer activity against HCT116 colorectal cancer cell. Our bioassay-guided phytochemical investigation of the roots of B. balansae led to the identification of 14 compounds including seven lignans (1-7), three phenylbenzene derivatives (8-10), two flavanone (11-12), and two triterpenoids (13-14). Among them, 4'-demethyl-4-deoxypodophyllotoxin (1) is the first aryltetralin lignan compound identified from this plant species. In addition, the stereochemistry of 1 was validated by X-ray crystallography for the first time, and its distinguished cytotoxic effect on HCT116 cells with an IC50 value at 20 nM was induced via an apoptosis induction mechanism. Compound 1 could also significantly decrease the migration rate of HCT116 cells, indicating its potential application against cancer metastasis. The western blot analysis showed that 1 has the potential to inhibit cell proliferation and metastasis. Treatment of 1 resulted in the downregulation of matrix metalloproteinases 2 (MMP2) and p-Akt, while p21 was upregulated. Collectively, the present study on the phytochemical and biological profile of B. balansae has determined the plant as a useful source to produce promising anticancer lead compounds.
Collapse
Affiliation(s)
- Lihan Zhao
- School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China (K.-L.L.)
- Department of Biology, Georgia State University, Atlanta, GA 30303, USA
| | - Wen-Jian Xie
- School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China (K.-L.L.)
| | - Yin-Xiao Du
- School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China (K.-L.L.)
| | - Yi-Xuan Xia
- School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China (K.-L.L.)
| | - Kang-Lun Liu
- School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China (K.-L.L.)
| | - Chuen Fai Ku
- School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China (K.-L.L.)
| | - Zihao Ou
- Department of Materials Science and Engineering, Stanford University, Stanford, CA 94305, USA
| | - Ming-Zhong Wang
- College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China
| | - Hong-Jie Zhang
- School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China (K.-L.L.)
| |
Collapse
|
2
|
Leach MO. Magnetic resonance spectroscopy (MRS) in the investigation of cancer at The Royal Marsden Hospital and The Institute of Cancer Research. Phys Med Biol 2006; 51:R61-82. [PMID: 16790921 DOI: 10.1088/0031-9155/51/13/r05] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Developments in magnetic resonance spectroscopy (MRS) at The Royal Marsden Hospital and The Institute of Cancer Research are reviewed in the context of preceding developments in nuclear magnetic resonance (NMR) and MRS, and some of the early developments in this field, particularly those leading to human measurements. The early development of technology, and associated techniques for human measurement and assessment will be discussed, with particular reference to experience at out institutions. Applications using particular nuclei will then be described and related to other experimental work where appropriate. Contributions to the development of MRS that have been published in Physics in Medicine and Biology will be discussed.
Collapse
Affiliation(s)
- M O Leach
- Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, UK
| |
Collapse
|
3
|
van Laarhoven HWM, Punt CJA, Kamm YJL, Heerschap A. Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy. Crit Rev Oncol Hematol 2005; 56:321-43. [PMID: 15982898 DOI: 10.1016/j.critrevonc.2005.03.009] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2004] [Revised: 03/21/2005] [Accepted: 03/21/2005] [Indexed: 01/18/2023] Open
Abstract
(19)Fluorine magnetic resonance spectroscopy ((19)F MRS) offers unique possibilities for monitoring the pharmacokinetics of fluoropyrimidines in vivo in tumors and normal tissue in a non-invasive way, both in animals and in patients. This method may therefore be useful for predicting response to fluoropyrimidine-based therapy with or without the effects of modulating agents, and this may be of value for the individualization of anticancer therapy and the strategic development of new anticancer drugs. (19)F MRS has been very valuable in elucidating the basic aspects of fluoropyrimidine metabolism, especially in animal studies. Studies in humans have indicated its clinical potential, but widespread application has been hampered by the relatively low detection sensitivity of the method. The recent introduction of clinical MR scanners with magnetic fields above 1.5 T may stimulate increased clinical use of (19)F MRS.
Collapse
Affiliation(s)
- Hanneke W M van Laarhoven
- Department of Medical Oncology 550, University Medical Centre Nijmegen, P.O. Box, 9101 HB, Nijmegen, The Netherlands.
| | | | | | | |
Collapse
|